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We hypothesized that redox analysis could provide sensitive markers of the oxidative pathway associated to the presence
of an increasing number of cardiovascular risk factors (RFs), independently of type. We classified 304 subjects without
cardiovascular disease into 4 groups according to the total number of RFs (smoking, hypertension, hypercholesterolaemia,
hyperhomocysteinaemia, diabetes, obesity, and their combination). Oxidative stress was evaluated by measuring plasma total and
reduced homocysteine, cysteine (Cys), glutathione, cysteinylglycine, blood reduced glutathione, and malondialdehyde. Twenty-
seven percent of subjects were in group 0 RF, 26% in 1 RF, 31% in 2 RF, and 16% in ≥3 RF. By multivariable ordinal regression
analysis, plasma total Cys was associated to a higher number of RF (OR = 1.068; 95% CI = 1.027–1.110, P = 0.002). Total RF
burden is associated with increased total Cys levels. These findings support a prooxidant eﬀect of Cys in conjunction with RF
burden, and shed light on the pathophysiologic role of redox state unbalance in preclinical atherosclerosis.
1. Introduction
Cardiovascular risk factors (RFs), such as smoking, hyper-
tension, hypercholesterolaemia, diabetes mellitus, and hy-
perhomocysteinaemia, are closely related to the development
of atherosclerosis [1]. Several experimental and clinical stud-
ies support the notion that oxidative stress plays a significant
role in this process [2].
Hyperhomocysteinaemia is a nonclassical RF indepen-
dently associated to the development of cardiovascular dis-
ease [3]. The mechanism by which homocysteine promotes
the production of hydroxyl radicals and lipid peroxidation
initiators may be related to the reactivity of the sulfhydryl
group leading to homocysteine autooxidation and thio-
lactone formation. This is of clinical relevance, because
mild to moderate hyperhomocysteinaemia, even though not
atherogenic per se, may lead to progression of atherosclerosis
in concert with other classical RFs.
Other thiols might also be expected to confer increased
cardiovascular risk. Cysteine (Cys) exhibits chemical prop-
erties similar to homocysteine through its sulfhydryl (–SH)
group, and its levels in plasma are 20-fold higher than
homocysteine [4]. However, its potential noxious eﬀects in
cardiovascular disease have till now received little attention
[5–7].
Homocysteine and Cys react via redox pathways in the
extracellular space, and their reduced, oxidized, and protein-
bound forms participate in the dynamic system known as
redox thiol state. Since thiol/disulfide redox states, per se,
are crucial both in redox signalling and control and in
antioxidant protection, they play an important role in the
connection between environmental influences and progres-
sion of detrimental changes associated with the presence of
RF.
Epidemiological research documented an independent
U-shaped relationship between total Cys and overt cardio-
vascular disease, even after adjustment for homocysteine,
creatinine, and other cardiovascular RFs [7]. Indeed, another
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study reported that, among all thiols, the steady redox-state
of plasma Cys is the most oxidized one [8].
The aim of the present study was to investigate in a
population with no overt cardiovascular disease the rela-
tionship between the cardiovascular RF burden and redox
state and lipid peroxidation, in terms of aminothiol and free
malondialdehyde (MDA) concentrations.
2. Materials and Methods
2.1. Study Population. Weprospectively enrolled 304 subjects
(169 males, aged 53 (43–63) years) selected among 793
consecutive subjects, who had been referred to our centre for
evaluation of the redox pattern. Patients presenting the fol-
lowing were excluded from the study: moderate to severe kid-
ney dysfunction (serum creatinine ≥2mg/dL), uncontrolled
hypertension (blood pressure levels ≥180/110mmHg), con-
gestive heart failure, unstable angina, previous myocardial
infarction, angiographically documented coronary artery
disease, ischemic stroke, known neoplasms, ongoing infec-
tion, immune system disease, type 1 or type 2 diabetes mel-
litus with micro- or macrovascular complications, advanced
liver disease, and alcohol abuse meeting the criteria of DSM-
III-R American Psychiatric Association [9].
No subject had been treated with antioxidant vitamins
supplement, N-acetylcysteine, or Cys supplements within 2
months before enrolment.
Written informed consent for study participation was
obtained from all patient. The study protocol was approved
by the Niguarda Hospital Ethics Committee.
2.2. RF Assessment. Details on commonly implicated RFs
and general dietary and medical history and lifestyle infor-
mation were obtained from each subject using a question-
naire. Assessed RFwere smoking, hypertension, hypercholes-
terolaemia, hyperhomocysteinaemia, uncomplicated type 2
diabetes, and obesity. Subjects were considered smokers
if they had smoked at least 10 cigarettes per day in the
previous year, with no interruption longer than 3 months
[10]. Hypertension was defined as systolic blood pressure
>140mmHg and/or diastolic blood pressure >90mmHg
on repeated measurements or on current treatment with
antihypertensive agents; lower blood pressure cutoﬀ val-
ues (systolic blood pressure >130mmHg and/or diastolic
blood pressure >80mmHg) were used to identify dia-
betic subjects as hypertensive [11]. Hypercholesterolaemia
was defined as low-density lipoprotein (LDL) cholesterol
level ≥160mg/dL or current treatment with lipid-lowering
medications [12]. Hyperhomocysteinaemia was defined as
total plasma homocysteine ≥15 μmol/L [13]. Type 2 dia-
betes mellitus was defined using established criteria [14]
or by being on current treatment with hypoglycaemic
agents. Obesity was defined as body mass index ≥30 kg/m2
[15].
We assessed the clustering of RFs (smoking, hyperten-
sion, hypercholesterolaemia, hyperhomocysteinaemia, dia-
betes, and obesity) for each subject, with a range of 0 (none
of these conditions) to ≥3 (three or more conditions).
2.3. Blood Sample Collection. Peripheral venous blood was
sampled in the morning after overnight fasting in the sitting
position. Blood samples were collected in the Vacutainer
tubes and immediately processed for blood, plasma, and
serum determinations.
2.4. Redox State Determination. The endogenous redox
state, defined as reduced and oxidized aminothiol equi-
librium, was evaluated by measuring blood and plasma
concentration of reduced and total homocysteine, Cys,
glutathione, and cysteinylglycine. For total aminothiols,
an aliquot of whole blood was diluted with an equal
volume of distilled water and frozen in liquid nitrogen;
the remaining blood was centrifuged (2000 g for 10min
at 4◦C) within 10 minutes of collection to obtain plasma,
which was aliquoted, frozen, then stored at −80◦C, and
analyzed within 1 week. The total forms measured in our
laboratory include the oxidized aminothiols (disulfides), all
conjugated forms (among them protein-bound aminoth-
iols and mixed aminothiols-disulfides produced through
oxidative processes or thiol-disulfide exchange reactions),
and reduced free aminothiols. Blood and plasma reduced
aminothiols were determined by prompt acidification with
10% trichloroacetic acid (1 : 1, v/v), protein precipitation,
and sample derivatization with ammonium-7-fluorobenzo-
2-oxa-1,3-diazole-4-sulphonate, a specific reagent for –SH
groups. Plasma total aminothiols were instead measured
after a reducing step with tri-n-butylphosphine, followed
by sample derivatization with the same agent described
below. Thiol concentrations were determined by isocratic
high-performance liquid chromatography (HPLC; Varian,
Surrey, UK) on a Discovery C18 column (250 × 4.6mm
I.D, Supelco, Sigma-Aldrich) and eluted with a solution
of 0.1mol/L potassium dihydrogenphosphate-acetonitrile
(92 : 8, v/v), pH 2.1, at a flow rate of 1mL/min, as previously
described [16–18]. Fluorescence intensities were measured
with excitation λ at 385 nm and emission λ at 515 nm, using
a JASCO fluorescence spectrophotometer.
2.5. Lipid Peroxidation Assessment. Levels of free MDA, the
reactive nonconjugated MDA form, were assessed in stored
plasma using selected ion-monitoring gas chromatography-
mass spectrometry (GC-MS, Hewlett-Packard Company,
Palo Alto, Calif, USA) in electron impact mode, equipped
with an HP-5 fused silica capillary column (25m, 0.32mm
I.D., 0.25 μm film thickness). Plasma samples were spiked
with dideuterated internal standard and derivatized with
phenylhydrazine hydrochloride before GC-MS analysis. The
UV determinations were carried out with a Perkin-Elmer
Lamda-11 spectrophotometer [19]. Values are expressed in
μmol/L.
2.6. Other Chemical Evaluations. Vitamin B12 and folates
were measured by competitive immunoassay using direct
chemiluminescence, while glucose, creatinine, fibrinogen,
total cholesterol, and triglycerides were determined using
standard laboratory methods. High-density lipoprotein
(HDL) cholesterol was measured after precipitation with
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Table 1: Clinical and biochemical characteristics according to risk factors burden.
All patients
(n = 304)
Group 0
(n = 81)
Group 1
(n = 95)
Group 2
(n = 80)
Group 3
(n = 48)
Age (years) 53 [43; 63] 44 [34; 53] 49 [39; 60] 59 [50; 67] 59 [53; 66]
Male gender (%) 169 (56%) 35 (43%) 51 (54%) 52 (65%) 31 (65%)
Body mass index (kg/m2) 25 [22; 28] 22 [21; 25] 25 [23; 27] 25 [23; 28] 28 [26; 31]
Fasting glucose (mg/dL) 93 [84; 109] 87 [80; 89] 89 [82; 96] 98 [87; 125] 120 [100; 147]
Total cholesterol (mg/dL) 200 [176; 230] 195 [171; 226] 197 [173; 216] 204 [179; 248] 217 [185; 244]
HDL cholesterol (mg/dL) 56 [47; 67] 63 [51; 73] 56 [50; 65] 50 [42; 62] 52 [46; 66]
LDL cholesterol (mg/dL) 117 [96; 146] 104 [84; 137] 118 [102; 141] 122 [98; 166] 115 [98; 164]
Triglycerides (mg/dL) 106 [71; 145] 85 [55; 127] 92 [61; 124] 127 [91; 174] 129 [96; 212]
Creatinine (mg/dL) 0.83 [0.70; 0.98] 0.83 [0.72; 0.99] 0.79 [0.68; 0.97] 0.84 [0.70; 0.99] 0.89 [0.72; 1.01]
Serum folate (ng/mL) 6.1 [4.6; 8.1] 6.2 [4.8; 8.8] 6.1 [4.5; 7.8] 5.3 [4.1; 7.7] 7.5 [5.5; 9.9]
Vitamin B12 (pg/mL) 396 [284; 530] 465 [367; 588] 362 [275; 450] 386 [265; 532] 365 [230; 501]
Data are expressed as median value and interquartile range [I; III] or number of patients (percentage).
dextran sulfate-magnesium and LDL cholesterol was calcu-
lated using Friedewald’s method.
2.7. Statistical Analysis. Discrete variables are presented as
frequency percent. Continuous variables are expressed as
median and interquartile range [I; III]. Univariable ordinal
logistic regression analysis was used to study the association
between the cumulative number of RFs and clinical, bio-
chemical, and redox state variables, adjusting for age and
gender. Results are presented as odds ratio (OR) and their
95% confidence interval (CI). Significant variables (P < 0.1)
were entered in the final multivariable model.
The statistical analyses were carried out with the Statis-
tical Package for the Social Sciences (SPSS Inc., Chicago, Ill,
USA), Release 10.0 for Windows.
3. Results
Cardiovascular RF distribution in the study population was
as follows: smoking (n = 86, 28%), hypertension (n =
102, 33%), hypercholesterolaemia (n = 77, 25%), diabetes
(n = 50, 16%), hyperhomocysteinaemia (n = 72, 24%), and
obesity (n = 34, 11%).
Study subjects were categorized into 4 groups based on
the number of cardiovascular RFs (group 0, 1, 2, and 3 if ≥3
RF). The control group included 81 (group 0, 27%) subjects,
while 95 (group 1, 31%) had 1 RF, 80 (group 2, 26%) had 2,
and 48 (group 3, 16%) had 3 or more RFs.
We performed an analysis on the clustering of RF, irre-
spective of type. The clinical and biochemical characteristics
of the RF groups are described in Table 1, and the redox state
profile is described in Table 2. Patients with more RF were
older and more frequently males and had higher levels of
fasting glucose, total cholesterol, and triglycerides than those
with less or no RFs. As regards the redox pattern, plasma total
Cys and plasma free MDA levels increased with RF number,
although without achieving statistical significance, while the
other variables did not show any marked linear trend.
Current drug treatment of study subjects is shown in
Table 3. No subject in group 0 tookmedications. As expected,
consistently with current guideline recommendations, the
proportion of subjects who took drugs for the treatment
of specific RF, in most instances with drug classes with
recognized antioxidant properties, increased with increasing
RF number.
The association between biochemical and redox state
variables and the RF burden was tested by univariable ordinal
logistic regression analysis, with age and gender as covariates,
to adjust for the observed unbalance in study groups. All the
variables that reached the significance level P < 0.10 (Table 4)
were entered into the final multivariable ordinal regression
model. The analysis revealed that plasma total Cys (OR =
1.068; 95% CI = 1.027–1.110, P = 0.002) was the sole redox
state variable independently associated with the number of
RFs. Distribution of plasma total Cys levels according to RF
burden is shown in Figure 1. The only other independent
predictor of RF burden was the number of administered
medications (OR = 3.710; 95% CI = 2.680–5.136, P < 0.001).
4. Discussion
In the present study, we analyzed in a large number of
subjects without overt cardiovascular disease the association
between the total RF burden and the redox state. Among all
redox variables, total Cys was the only parameter significantly
associated to RF burden.
Many cardiovascular RFs physiologically interact in the
aetiology of cardiovascular disease. In addition, clustering
of RFs is frequent and may increase the risk multiplicatively
[20].
The potential vascular toxicity of Cys has recently been
emphasized, though this aminothiol has not been as widely
studied as homocysteine. In vitro, autooxidation of Cys
occurs more readily than that homocysteine, thereby gener-
ating reactive oxygen species that can, by oxidation, mod-
ify low-density lipoproteins [21]. Additionally, Cys eﬀects
endothelium-dependent contraction by generating O·−2 ,
which rapidly inactivates the endothelium-derived relaxing
factor [22]. In the experimental setting, auto-oxidation of
homocysteine was found to be dramatically accelerated by
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Table 2: Redox characteristics according to risk factors burden.
All patients
(n = 304)
Group 0
(n = 81)
Group 1
(n = 95)
Group 2
(n = 80)
Group 3
(n = 48)
Plasma total thiols (μm/L)
Homocysteine 9.5 [7.4; 14.1] 9.0 [7.1; 10.9] 9.2 [7.4; 13.8] 11.5 [7.8; 18.6] 9.9 [7.5; 19.0]
Cysteine 250 [210; 291] 228 [197; 269] 253 [203; 280] 260 [223; 305] 280 [230; 320]
Cysteinylglycine 30.8 [23.9; 41.9] 32.7 [24.7; 43.4] 30.2 [24.0; 44.0] 31.1 [23.7; 37.6] 29.9 [22.4; 37.3]
Glutathione 5.5 [4.1; 7.3] 5.9 [4.3; 8.0] 5.6 [4.0; 7.0] 5.4 [4.2; 7.3] 5.5 [3.7; 0.7.5]
Plasma reduced thiols (μm/L)
Homocysteine 0.16 [0.10; 0.24] 0.13 [0.10; 0.21] 0.16 [0.10; 0.24] 0.19 [0.11; 0.29] 0.14 [0.07; 0.28]
Cysteine 7.9 [5.7; 9.4] 7.9 [6.2; 9.0] 7.7 [5.7; 9.1] 7.9 [5.7; 10.0] 8.1 [5.7; 10.1]
Cysteinylglycine 3.3 [2.1; 4.5] 3.5 [2.2; 5.3] 3.5 [2.1; 4.9] 3.3 [2.2; 4.3] 2.9 [1.4; 3.7]
Glutathione 1.9 [1.3; 3.8] 1.9 [1.3; 3.9] 1.8 [1.1; 3.5] 2.1 [1.4; 4.2] 2.1 [1.3; 4.4]
Free malondialdehyde (μmol/L) 0.76 [0.47; 1.35] 0.62 [0.36; 0.89] 0.70 [0.45; 1.30] 0.94 [0.68; 1.33] 1.26 [0.65; 1.49]
Blood reduced glutathione (μmol/L) 655 [496; 824] 655 [451; 821] 705 [536; 859] 663 [454; 842] 569 [499; 771]
Data are expressed as median value and interquartile range [I; III].
Table 3: Current medications in risk factor groups.
Total
(n = 223)
Group 1
(n = 95)
Group 2
(n = 80)
Group 3
(n = 48)
ACE inhibitors 43 (19%) 3 (3%) 20 (25%) 20 (42%)
Angiotensin II receptor antagonists 18 (8%) 4 (4%) 6 (7%) 8 (17%)
beta-blockers 27 (12%) 2 (2%) 14 (17%) 11 (23%)
Diuretics 11 (5%) 3 (3%) 3 (4%) 5 (10%)
Calcium-channel blockers 36 (16%) 3 (3%) 19 (24%) 14 (29%)
Antiplatelet agents 28 (12%) 6 (6%) 13 (16%) 9 (19%)
Statins 33 (15%) 3 (3%) 12 (15%) 18 (38%)
Antidiabetic agents 42 (19%) 7 (7%) 16 (20%) 19 (40%)
Number of drugs∗ 1 [0; 2] 0 [0; 1] 1 [0; 2] 2 [1; 3]
Data are expressed as number of patients (percentage).
∗Number of drugs: sum of all drug classes reported above in the table, presented as median and interquartile range [I; III].
ACE: angiotensin converting enzyme.
Table 4: Age and gender-adjusted ordinal logistic regression analysis versus number of risk factors.
P value Adjusted OR 95% CI
Creatinine (mg/mL) 0.14 0.384 0.107–1.377
Serum folate (ng/mL) 0.96 1.002 0.930–1.079
Vitamin B12 (pg/mL) 0.06 0.999 0.998–1.011
Plasma total thiols (μm/L)
Cysteine 0.03 1.004 1.002–1.008
Cysteinylglycine 0.28 1.007 0.995–1.020
Glutathione 0.21 1.052 0.970–1.140
Plasma reduced thiols (μm/L)
Cysteine 0.77 1.009 0.951–1.070
Cysteinylglycine 0.60 0.977 0.894–1.067
Glutathione 0.08 1.064 0.992–1.142
Free malondialdehyde (μmol/L) 0.12 1.438 0.905–2.283
Blood reduced glutathione (μmol/L) 0.86 1.000 0.998–1.002
Number of drugs <0.001 2.983 2.303–3.864
OR, odds ratio; CI, confidence interval.
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Figure 1: Plasma total cysteine and risk factors burden in study sub-
jects. Raised plasma total cysteine concentrations are independently
associated with the presence of a higher number of risk factors.
The box plots (μmol/L) show values expressed as median (50th
percentile), interquartile ranges (25th and 75th percentiles, box),
and extreme values (whiskers) of total plasma cysteine in relation
to risk factor grouping in subjects without (0) and with (1, 2, and
3) cardiovascular risk factors.
the presence of either Cys or cystine [23]. Cys, and not
homocysteine, has demonstrated a high reactivity towards
DNA, both in the absence and presence of copper(II), leading
to the formation of reactive species and the induction of
oxidative stress [24]. Finally, Cys more readily undergoes
autooxidation at physiologic pH, because of its lower pK
values than all other thiols [21].
In our series, plasma reduced Cys showed no consistent
trend in relation with the number of RF. Therefore, the
direct association of plasma total Cys, which includes free
reduced, free oxidized, and protein-bound forms, with a
greater RF burden may be ascribed mainly to increased Cys
oxidation processes. These covalent modifications favour an
enhanced oxidative alteration, which leads to changes in
protein structure and function.
Our results are in agreement with previous reports of
increased total Cys levels in patients with vascular diseases
[7]. However, those studies were performed on subjects with
preexisting disease; thus, the possibility that Cys might be
marker of the disease itself, and not feature involved in its
progression, cannot be ruled out. Conversely, in our series
we observed a chronic disturbance of the cellular redox state,
in terms of high total Cys levels, in the absence of overt
vascular disease. Indeed, we recently showed, in otherwise
healthy subjects, that Cys is a stronger marker of endothelial
dysfunction, in terms of abnormal flow-mediated dilation,
than clinical and all other biochemical variables explored
in that study, including homocysteine levels at baseline and
after methionine load [25].
Previous work on plasma thiol oxidation in healthy
subjects [26, 27] described an association between total
Cys and older age, male gender, body mass index (BMI),
higher cholesterol, and diastolic blood pressure. Further-
more, higher levels of these risk factors were found to be
associated with significant increases in total Cys with time.
Our findings confirm that, in the presence of cardiovascular
RF, a “thiol stress” is the major demonstrable alteration in
plasma redox biochemistry, and its extent, in terms of Cys
oxidation, is related to the total RF burden.
Many forms of thiol oxidation are reversible. These
modifications, considered as “redox regulation” rather than
“oxidative stress”, comprise mainly the formation of mixed
disulphides between proteins and glutathione. It has been
suggested that the increased vascular risk associated with
elevated plasma tHcy may be partly explained by an associ-
ated fall in plasma total Cys [28]. However, other reports [8,
29] demonstrated that in healthy normohomocysteinaemic
subjects, Cys tended to be more oxidized than glutathione.
These authors suggested that, while the redox state of plasma
glutathione is a response to both intracellular and extracel-
lular oxidative processes, Cys redox state more accurately
reflects the increased oxidative events in aging. Our findings
in subjects without cardiovascular disease shed light on the
prooxidant eﬀect of Cys in conjunction with the RF burden.
The lack of association between plasma glutathione and
RF burden might be ascribed to the higher proportion in
group 2 and 3 of subjects treated by drug classes known to
influence the antioxidant profile. Therefore, the susceptibility
to disease progression should be ascribedmainly to increased
oxidative processes, in terms of higher total plasma Cys levels,
rather than to weakening of the antioxidant defence.
Free MDA is a well-known index of lipid peroxidation
and marker of oxidative stress. In our study population,
MDA levels showed an increasing trend (Table 2) in the
unadjusted regression analysis, but no relationship between
MDA and RF was evident after controlling for age and
gender. Indeed, the smaller size and wider variations inMDA
levels or the higher proportion of subjects on drug treatment
in group 3 subjects might have mitigated the severity of
oxidative stress, in terms of lipid peroxidation [30, 31].
Some limitations of our study should be considered.
First, according to the known distribution of RF in the
general population, an unbalance in age and gender was
present in this series; to minimize its impact, we controlled
for these factors in the statistical analysis.
We did not directly measure oxidized glutathione and
Cys, so we could not reliably determine the redox state of
the reduced/oxidized gluthatione and Cys pair, which were
both recently found predictive of increased intima-media
thickness in healthy subjects free from cardiovascular RFs
[32]. However, to optimize preanalytical procedures for the
assessment of redox markers in estimating cardiovascular
risk, a more rapid collection and processing of samples, such
as the one adopted for total and reduced rather than oxidized
forms determination, are warranted.
We performed a separate analysis according to risk
factor type, to elucidate whether specific risk factors were
associated with a diﬀerent redox pattern. Among redox
variables, onlyMDAwas associated with a specific risk factor,
unsurprisingly hypercholesterolemia. However, the number
of patients with a single risk factor in this series was low to
derive definite conclusions from this finding.
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Finally, the demonstrated association between RF burden
and number of daily administered drugs appears obvious.
We specifically decided to test this association because we
wished to verify whether drugs with antioxidant properties
would aﬀect the redox state in diﬀerent RF groups; total Cys
remained independently associated to a higher RF burden
when controlling for treatment. Furthermore, antioxidant
drug treatment should have weakened, rather than increased,
the diﬀerence in total Cys between RF groups.
In conclusion, our findings and the variable number
of RFs support a prooxidant eﬀect of Cys in conjunction
with RFs in subjects without cardiovascular disease burden
and shed light on the pathophysiologic role of redox state
unbalance in preclinical atherosclerosis. The next step will be
to verify the predictive capability of these biomarkers over a
long follow-up period.
Since management of cardiovascular risk in asymp-
tomatic individuals focuses on assessing traditional RFs,
estimating risk, and modifying RFs through lifestyle changes
or drug treatment, markers of possible mediators of the
disease or noninvasive procedures that test for the likelihood
of atherosclerotic burden are advisable. As pro-oxidant
processes are involved in the initial phases of atherosclerosis,
sensitive and cheap redox parameters appear helpful in
risk assessment, to better identify asymptomatic subjects
at high-intermediate risk. Those patients might benefit by
therapeutic strategies able to provide the first line of defence
during peroxyl radical attack; this concept should be the basis
of intervention studies.
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